James M. Wilson, MD, PhD, director of the Gene Therapy Program at the University of Pennsylvania, and a co-founder of Passage Bio. Passage Bio, a developer of gene therapies for rare monogenic CNS ...

Recognition underscores CrossBridge Bio’s leadership in advancing next-generation dual-payload ADCs toward the clinic. CrossBridge Bio, a biopharmaceutical company pioneering next-generation ...

Oncology drug developer Boundless Bio (BOLD) has filed for a proposed $100M initial public offering. Boundless Bio didn’t state any terms in its SEC filing, but indicated it was looking to raise ...

B cells of the immune system consistently produce vast quantities of proteins. Be Biopharma is harnessing that capability for a new type of cell therapy and the biotech company now has $130 million to ...

Lifecore Biomedical has been selected by Humanetics Corporation to provide contract development and manufacturing services to support the development of BIO 300, a radioprotective agent aimed at ...

Generation Bio, a developer of redosable gene therapies, said today it has closed on a $100 million Series B financing, with proceeds intended to advance its first two treatment candidates through ...

HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company has entered into a ...

JUPITER, Fla. and WAGENINGEN, Netherlands, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”), a global biotechnology company producing precision-engineered, animal-free proteins ...

Passage Bio, a preclinical biotech developing gene therapies for rare CNS disorders, raised $216 million by offering an upsized 12 million shares at $18, the high end of the range of $16 to $18.